Praxis Precision Medicines, Inc.

Developing precision medicines for CNS disorders. Relutrigine is under FDA Priority Review for SCN2A/SCN8A developmental and epileptic encephalopathies.

Back to company catalog

Neurology · Small molecules and antisense oligonucleotides · NDA under FDA Priority Review

Compare report options